TY - JOUR
T1 - Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy
AU - MacLennan, Jenny M.
AU - Obaro, Stephen
AU - Deeks, Jonathan
AU - Lake, Derrick
AU - Elie, Cheryl
AU - Carlone, George
AU - Moxon, E. Richard
AU - Greenwood, Brian
N1 - Funding Information:
Financial support: National Meningitis Trust; World Health Organization and United Kingdom Medical Research Council provided financial support for the initial trial.
PY - 2001
Y1 - 2001
N2 - Infant vaccination with meningococcal conjugates may provide long-term protection against disease. Antibody levels and immunologic memory were assessed in 5-year-old Gambian children who received meningococcal A/C conjugate vaccination (MenA/C) in infancy. At 2 years, they were randomized to receive a booster of MenA/C (conjugate group), meningococcal A/C polysaccharide (MPS group), or inactivated polio vaccine (PV group). All groups were revaccinated with 10 μg MPS at 5 years of age, as were 39 previously unvaccinated age-matched control subjects. Before revaccination, titers were higher in the conjugate and MPS groups than in control subjects (P<.001); titers for the IPV group were similar to those for control subjects. Ten days after revaccination, the conjugate and IPV groups had similar serogroup C serum bactericidal antibody titers (3421 vs. 2790, respectively). These levels were significantly higher than those in the MPS (426) and control (485) groups (P< .001). Thus, immunologic memory was sustained for ≥5 years; however, MPS challenge at 2 years interfered with a subsequent memory response.
AB - Infant vaccination with meningococcal conjugates may provide long-term protection against disease. Antibody levels and immunologic memory were assessed in 5-year-old Gambian children who received meningococcal A/C conjugate vaccination (MenA/C) in infancy. At 2 years, they were randomized to receive a booster of MenA/C (conjugate group), meningococcal A/C polysaccharide (MPS group), or inactivated polio vaccine (PV group). All groups were revaccinated with 10 μg MPS at 5 years of age, as were 39 previously unvaccinated age-matched control subjects. Before revaccination, titers were higher in the conjugate and MPS groups than in control subjects (P<.001); titers for the IPV group were similar to those for control subjects. Ten days after revaccination, the conjugate and IPV groups had similar serogroup C serum bactericidal antibody titers (3421 vs. 2790, respectively). These levels were significantly higher than those in the MPS (426) and control (485) groups (P< .001). Thus, immunologic memory was sustained for ≥5 years; however, MPS challenge at 2 years interfered with a subsequent memory response.
UR - http://www.scopus.com/inward/record.url?scp=0035171737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035171737&partnerID=8YFLogxK
U2 - 10.1086/317667
DO - 10.1086/317667
M3 - Article
C2 - 11087205
AN - SCOPUS:0035171737
SN - 0022-1899
VL - 183
SP - 97
EP - 104
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -